Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30527264 | 0.84 | ENPP2 (0.42) | BCAT2ENPP2 | |
| SCHEMBL775432 | 0.78 | PTGES2 (0.46) | ACLYADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL6828498 | 0.78 | CDK2 (0.48) | ERN1BCAT2ENPP2 | |
| SCHEMBL514170 | 0.78 | ALDH1A1 (0.44) | ACLYHSD11B1 | |
| SCHEMBL13211321 | 0.77 | SLC40A1 (0.44) | ACLYADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL2642083 | 0.77 | ADRA2A (0.39) | ACLYADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4605735 | 0.75 | CDK2 (0.42) | ADRA2AADRA2CCCR2BCAT2ENPP2 | |
| SCHEMBL6129256 | 0.75 | ADRA2A (0.38) | ACLYADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL6286174 | 0.75 | TTR (0.46) | ACLYBCAT2ENPP2PIK3CA | |
| SCHEMBL2642805 | 0.75 | HSD11B1 (0.42) | ACLYCCR2PTGS2BCAT2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1313707-B1 | QUINOLINE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | HOFFMANN LA ROCHE (CH) | 2007-07-18 | — | — | EP | disclosed |
| US-7186840-B2 | Quinoline derivatives as anti-inflammatory agents | ROCHE PALO ALTO LLC (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-7049325-B2 | Quinoline derivatives as anti-inflammatory agents | SYNTEX (U.S.A.) LLC (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060084677-A1 | Quinoline derivatives as anti-inflammatory agents | BROKA CHRIS A | 2006-04-20 | — | — | US | disclosed |
| CN-1199950-C | Quinolene derivatives as anti-inflammation agents | HOFFMANN LA ROCHE (CH) | 2005-05-04 | — | — | CN | disclosed |
| CN-1466575-A | Quinoline derivatives as anti-inflammatory agents | - | 2004-01-07 | — | — | CN | disclosed |
| EP-1313707-A1 | QUINOLINE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | SNYTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002012192-A1 | QUINOLENE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084677-A1 | Quinoline derivatives as anti-inflammatory agents | NR5A2, PTGER4, IL5 | ALB 3077/4885ERN1 3704/4885ACLY 3472/4885 |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | CNR1, CNR2, PTGER4 | ALB 3149/4885ERN1 2804/4885ACLY 2868/4885 |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | ALB 3482/4885ERN1 1896/4885ACLY 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.